CCR5 and metabolic dysfunction-associated steatohepatitis: (Parthasarathy and Malhi, 2021; Zhang and Yang, 2021) Cenicriviroc (CVC) is an oral dual CCR2/CCR5 antagonist, which has shown promising results in murine NAFLD models and was further evaluated in NASH-related clinical trials.